Sernova ( (TSE:SVA) ) has shared an announcement.
Sernova Biotherapeutics has received FDA clearance for its Investigational New Drug application to evaluate the Cell Pouch bio-hybrid organ with auto-transplanted thyroid cells in patients undergoing thyroid surgery. This development marks a significant step forward in Sernova’s efforts to provide a long-term solution for hypothyroidism without the need for hormone replacement or immune suppression. The clearance allows Sernova to expand its clinical trials and strengthen its position in the regenerative medicine field.
More about Sernova
Sernova Biotherapeutics is a clinical-stage regenerative medicine company focused on developing bio-hybrid organs using its Cell Pouch technology combined with human donor or stem cell-derived therapies. The company aims to treat chronic diseases, with an initial focus on type 1 diabetes and thyroid disorders.
YTD Price Performance: -13.04%
Average Trading Volume: 129,539
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$65.7M
For an in-depth examination of SVA stock, go to TipRanks’ Stock Analysis page.